Morgan Stanley again adjusts its Fed forecast, now sees 4 cuts in 2026
NEW YORK - Herbalife Ltd. (NYSE:HLF), a $1 billion market cap nutrition company currently trading at a modest P/E ratio of 3.6, introduced MultiBurn, a new dietary supplement formulated with botanical extracts designed to support weight loss and metabolic health, according to a company press release issued Monday.
The supplement contains three main botanical ingredients: Morosil from Moro blood oranges, which the company says supports overall weight loss; Metabolaid®, a hibiscus and lemon verbena extract blend aimed at healthy fat reduction; and Capsifen™, a red chili pepper and fenugreek combination intended to support energy expenditure. According to InvestingPro data, Herbalife has demonstrated strong recent momentum with a 49.6% price return over the past six months, though technical indicators suggest the stock may be overbought.
The product is gluten-free, vegan-friendly, and made without synthetic colors or dyes. It is designed to be taken as three capsules once daily with breakfast or lunch.
"MultiBurn was developed using scientific insight into the underlying mechanisms of metabolic health," said John Heiss, Ph.D., vice president of Global Product Innovation at Herbalife, in the press release.
The company recommends using the supplement alongside a balanced diet and regular physical activity. MultiBurn can also complement other Herbalife products such as protein shakes and fiber supplements.
The product is currently available in the United States and will launch in Puerto Rico in September 2025. Herbalife products are sold exclusively through the company’s network of independent distributors.
Herbalife, which describes itself as the "#1 active and lifestyle nutrition brand in the world," has been in business for 45 years and operates in more than 90 markets globally. The company generates nearly $5 billion in annual revenue and maintains a "GREAT" financial health score according to InvestingPro analysis, which offers 12 additional investment tips and comprehensive financial metrics for this stock.
The company notes that statements about the product’s effects have not been evaluated by the Food and Drug Administration and that the supplement is not intended to diagnose, treat, cure, or prevent any disease. While the stock shows strong recent performance, InvestingPro analysis indicates that net income is expected to decline this year, making it crucial for investors to monitor the impact of new product launches like MultiBurn on the company’s financial performance.
In other recent news, Herbalife reported its first-quarter earnings for 2025, showcasing a strong performance with earnings per share (EPS) of $0.59, surpassing analyst expectations of $0.40. Despite this earnings beat, the company slightly missed its revenue forecast, reporting $1.22 billion against a projected $1.23 billion. The company also increased its adjusted EBITDA by 19% year-over-year, reaching $165 million, highlighting improved operational efficiency. Herbalife’s management revised its full-year 2025 constant currency sales guidance to a range of 0.5% to 5.5% growth and raised its adjusted EBITDA outlook to between $625 million and $655 million.
Additionally, the company noted robust new distributor growth, with a 16% year-over-year increase. However, there were challenges in the North American market, leading to concerns about the timing of a sales turnaround in the U.S. market. Citi analyst Chasen Bender responded to these developments by lowering Herbalife’s stock price target from $13 to $11, while maintaining a Buy rating, reflecting confidence in the company’s strategic initiatives. Bender pointed to cost pressures from the launch of a new product, Pro2col, but also noted potential savings in technology and administrative expenses.
Herbalife’s recent strategic acquisitions, including Protocol Health and Link Biosciences, aim to bolster future growth prospects by enhancing the company’s product offerings and technology platform. These acquisitions are seen as crucial steps in Herbalife’s strategy to expand its reach through technology and personalization. The company’s management remains optimistic about achieving the updated sales guidance, supported by consistent growth in new distributor numbers over the past four quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.